An observational study in Psychotic Disorder, sponsored by Philipp Homan. Recruiting at 7 sites in 6 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Philipp Homan · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Psychotic Disorders with a site in Switzerland — 10 open to participants now, 11 under way, 3 of them phase 3. Psychotic Disorders · Switzerland.
Among the 25 studies in Psychotic Disorders with a site in Switzerland, this one is one of 3 that started in 2026, is one of 5 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 25th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →10 of the 25 studies in Psychotic Disorders with a site in Switzerland are open now. Recruiting first, the newest first:
University of Oxford · Sites in Switzerland, Austria, Germany and 6 more countries
Ages 16–40
Marco Armando · Sites in Switzerland
Ages 14–30
Tobias Melcher · Sites in Switzerland
Ages 55+
Indrit Begue · Sites in Switzerland
Ages 18–65
Psychiatric University Hospital, Zurich · Sites in Switzerland
Ages 18–65
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 360 is above the median of 123 across 221 observational studies indexed under Psychotic Disorders.
Median enrollment 100 across the 20 interventional studies, 156 across the 5 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Philipp Homan as lead sponsor.
Philipp Homan has 1 study filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Psychotic Disorders with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
| NCT07060742Tobias MelcherStudy on the Use of Exergames to Support Older Adults With Psychosis | 2027-05-15 |
| NCT05911529Psychiatric University Hospital, ZurichTracking the Linguistic Signatures of Motivational Interviewing in Acute Psychosis | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Psychotic Disorders with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.
This project follows a prospective, exploratory, observational design with a non-randomized, two-arm structure, including a group of individuals with psychosis at risk of relapse and a healthy control group. As a multicenter, international research project, it will assess the usability and feasibility of speech data collection across 6 different languages (English, German, French, Dutch, Czech and Turkish) and healthcare systems, ensuring its applicability in diverse clinical environments.
Speech and self-report data will be collected weekly for a year using a finalized smartphone application, ensuring consistency and feasibility in real-world clinical settings. The recordings will be securely transferred to an external platform for AI-based analysis, preventing any direct impact on clinical decision-making and maintaining the study's observational nature.
To ensure data integrity and reliability, a Human-in-the-Loop (HITL) quality control process is implemented after each speech recording session:
Initial Data Review: a designated reviewer (HITL1) checks the audio quality and accuracy of automated transcripts stored securely in the Trusted Secure Database (TSD) system in Norway. They correct transcription errors and flag anomalies such as poor audio quality to maintain data accuracy for analysis.
Risk Assessment and Decision Suggestion: a second reviewer (HITL2) evaluates the data by: (i) assessing speech characteristics relevant to relapse risk based on raw response data and performance scores (e.g., story recall accuracy); (ii) providing an independent relapse risk estimate, without access to the automated AI-generated risk assessment, (iii) classify the participant as belonging to either the psychosis or healthy control group, and (iv) suggesting a clinical decision, which is recorded for research purposes but not shared with the treating clinician.
Apart from this Fast Diagnostic Loop, where a clinical decision will be made, an exploratory component will be incorporated to identify and validate new speech markers associated with relapse. This New Marker Discovery Loop will involve the search of additional speech features associated with relapse beyond the standard markers. The goal is to discover novel speech markers that may improve our understanding of relapse mechanisms and potentially serve as predictive or diagnostic tools for future clinical use.
For the 1-year follow-up period, participants will attend a total of three study visits. These visits will occur at the following time points: Visit 0: Baseline visit, Visit 1: 6 months post-baseline (±10 days), and Visit 2: 12 months post-baseline (±10 days). During these visits, participants from both groups will undergo assessments aiming to evaluate the usability and trustworthiness of the procedure and to assess various functional and quality-of-life outcomes.
Participants at risk of relapse will be recruited from clinical settings while in a stable phase of partial or full remission. Depending on the site, eligible individuals may be either inpatients nearing discharge or outpatients under ongoing care. If the treating clinician considers the patient's mental state sufficiently stable, the study information and consent process may be initiated during inpatient care, prior to discharge. For outpatients, participants may be contacted by phone, or the study can be presented during routine outpatient or day clinic visits.
Healthy participants will be recruited through community outreach, advertisements, and volunteer registries from universities and hospitals. healthy participants will be selected to match individuals with psychosis based on key characteristics such as age and sex in each site.
Healthy participants Inclusion Criteria:
Healthy participants Exclusion Criteria:
Individuals with psychosis Inclusion Criteria:
Individuals with psychosis Exclusion Criteria:
Citizens with psychiatric or somatic comorbidity, drug- or alcohol abuse will be allowed to participate, so that the sample will reflect the general population of citizens with psychosis and the study's endpoints will be generalizable.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals at risk of psychotic relapse
Other: Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
Healthy participants will be used as controls
Other: Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
The intervention is a weekly online assessment of speech, to detect subtle characteristics of psychotic speech. These recordings are made through a speech data collection tool: a smartphone app with implemented tasks for the collection of behavioral response data (speech and self-report). Data is then transferred to a safe repository (TSD) to be analysed by an AI-based speech data analysis algorithm: a backend system will run the predictor code to calculate automatic relapse risk scores.
Feasibility: User adherence
Proportion of users adhering to their allocated tasks. Task completion is automatically assessed for each user. A user is regarded as adherent, if they complete at least 33% of their tasks across all sessions.
Time frame: From enrollment to the end of the study at 12 months
Feasibility: Transcription quality
Proportion of users for which high quality transcripts are produced. Transcription quality is measured by the Word Error Rate (WER) between Automated Speech Recognition (ASR) and human corrected transcripts. A user with an overall WER of at most 35% is regarded as having high quality transcripts
Time frame: From enrollment to the end of the study at 12 months
Feasibility: Usability of recordings
Proportion of recordings that can be used by the AI algorithm. Usability of each record is assessed by HITL reviewers based on the three questions (i) has the user interpreted the question correctly, and (ii) is the audio (at least partially) audible and (iii) comprehensible. The three questions must both be answered with yes for the recording to be usable
Time frame: From enrollment to the end of the study at 12 months
Overall system usability
Proportion of users rating the app as usable. Usability is evaluated using the System Usability Scale (SUS), providing a standardized usability score (range 0-100) based on a 10-item questionnaire. We regard a score of at least 70 as usable.
Time frame: 6 months and 12 months
Performance of the monitoring system for relapse prediction
Assessed by the Area Under the Receiver Operating Characteristic Curve (AUC). Thresholds for relapse prediction will be explored as part of the analysis
Time frame: From enrollment to the end of the study at 12 months
Provider-perceived usability and usefulness
Provider-perceived usability and usefulness of the app will be assessed using the mHealth App Usability Questionnaire (MAUQ - Provider version). Scores will be reported by domain and overall
Time frame: 6 months and 12 months
Relapse Outcome 1
Relapse rate, defined as the proportion of participants experiencing at least one relapse (rehospitalization) during the study period.
Time frame: 6 months and 12 months
Relapse Outcome 2
Human-in-the-loop (HITL) relapse risk estimates and relapse incidence: HITL risk scores (range 0-1) will be categorized into low (0-0.2), medium (\>0.2-0.6), and high (\>0.6) risk levels. Descriptive analyses will assess the proportion of relapses within each category.
Time frame: From enrollment to the end of the study at 12 months
Relapse Outcome 3
Clinical decision support system (CDSS) relapse risk estimates and relapse incidence: CDSS risk scores (range 0-1) will be categorized into low, medium, and high risk using the same thresholds. Descriptive analyses will assess relapse proportions per category.
Time frame: From enrollment to the end of the study at 12 months
Relapse Outcome 4
Predictive performance of HITL relapse risk estimates will be evaluated using the area under the curve (AUC), with exploratory assessment of prediction thresholds.
Time frame: From enrollment to the end of the study at 12 months
Relapse Outcome 5
Concordance between CDSS and HITL relapse risk estimates will be assessed by evaluating the level of agreement between algorithm-based and clinician-based risk scores.
Time frame: From enrollment to the end of the study at 12 months
Recordings Outcome 1
Number of recordings per participant across all sessions.
Time frame: From enrollment to the end of the study at 12 months
Recordings Outcome 2
Interpretation of question: has the user interpreted the question correctly? Yes or no. Per recording.
Time frame: From enrollment to the end of the study at 12 months
Recordings Outcome 3
Audibility of audio: is the audio (at least partially) audible? Yes or no. Per recording.
Time frame: From enrollment to the end of the study at 12 months
Recordings Outcome 4
Comprehensibility of audio: is the audio (at least partially) comprehensible? Yes or no. Per recording
Time frame: From enrollment to the end of the study at 12 months
Speech-based features
Exploratory comparison analysis of speech-based features extracted using tools such as Prosogram or openSMILE.
Time frame: From enrollment to the end of study at 12 months.
Text-based features Outcome 1
In addition, robust text-based features like speech rate and pause rate will be derived using common Python libraries for Natural Language Processing (NLP) like NLTK and spaCy.
Time frame: From enrollment to the end of the study at 12 months.
Text-based features Outcome 2
WordNet will be used to analyze correctness of responses where appropriate (fluency task, story recall task, adapted Stroop task).
Time frame: From enrollment to the end of the study at 12 months
Neuroimaging-based features Outcome 1
Exploratory comparison analysis of features extracted from structural magnetic resonance imaging (sMRI) data.
Time frame: 6 months and 12 months
Neuroimaging-based features Outcome 2
Exploratory comparison analysis of features extracted from functional magnetic resonance imaging (fMRI) data.
Time frame: 6 months and 12 months
Neuroimaging-based features Outcome 3
Exploratory comparison analysis of features extracted from Diffusion Tensor Imaging (DTI) data.
Time frame: 6 months and 12 months
Social and occupational function of participants Outcome 1
Quality of life assessed with Quality of Life Scale (QoL). Assessed only in participants at risk of relapse
Time frame: Baseline, 6 months and 12 months
Social and occupational function of participants Outcome 2
Global Assessment of Functioning Scale (GAF): measures how much a person's symptoms affect their day-to-day life on a scale of 0 to 100. Assessed only in participants at risk of relapse
Time frame: 6 months and 12 months
Social and occupational function of participants Outcome 3
Social and Occupational Functioning Assessment Scale (SOFAS): a global rating of current social and occupational functioning with scores ranging from 0 to 100. It differs from GAF by focusing on social and occupational functioning independent of the overall severity of the individual's psychological symptoms. Assessed only in participants at risk of relapse
Time frame: 6 months and 12 months
Social and occupational function of participants Outcome 4
Number of psychiatric admissions. Assessed only in participants at risk of relapse
Time frame: 6 months and 12 months
Social and occupational function of participants Outcome 5
Duration (in weeks) of psychiatric admissions. Assessed only in participants at risk of relapse
Time frame: 6 months and 12 months
Social and occupational function of participants Outcome 6
Rates of self-harm (including suicide, suicide attempts and aggressive incidents) assessed with the Social Dysfunction \& Aggression Scale (SDAS). Assessed only in participants at risk of relapse
Time frame: 6 months and 12 months
Social and occupational function of participants Outcome 7
Positive and Negative Syndrome Scale (PANSS): measure the prevalence of positive and negative syndromes in schizophrenia. Scores will be reported by dimension (positive, negative, and general psychopathology) and overall. Assessed only in participants at risk of relapse
Time frame: 6 months and 12 months
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 36 months after the start.
Of 74 non-industry observational studies under Psychotic Disorders, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 124. This study's planned 36 months is below that.
Counting every sponsor, half of 76 studies reached it within 64 months; a quarter within 35 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.